• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Higher-dose primaquine has higher efficacy in preventing relapse of Plasmodium vivax malaria

byDavid XiangandHarsh Shah
April 22, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Compared to lower dose primaquine, higher dose primaquine had higher efficacy in preventing relapse of Plasmodium vivax malaria.

2. Higher dose primaquine demonstrated a significantly higher recurrence-free rate compared to lower dose primaquine.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Malaria is commonly caused by Plasmodium vivax and Plasmodium falciparum or mixed infections. Primaquine therapy offers potential for eradication of these parasites and hypnozoites, but its efficacy depends on the total dose given during a round of therapy (either 3.5mg or 7mg per kilogram of body weight), because of variable drug susceptibility worldwide. In most of the Americas, primaquine is given at a total dose of 3.5mg per kilogram. However, there is a gap in knowledge as to understanding the therapeutic efficacy of lower dose and higher dose primaquine. This study found that higher doses of primaquine had significantly higher efficacy in preventing relapse of Plasmodium vivax malaria. This study was limited by factors such as the limitations in the use of genotyping to categorize Plasmodium vivax recurrence since relapse can be caused by both homologous and heterologous hypnozoites. Nevertheless, these study’s findings are significant, as they demonstrate that a higher dose of primaquine had a higher recurrence-free percentage than those who received a lower total dose of primaquine for Plasmodium vivax malaria.

Click to read the study in NEJM

Relevant Reading: Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria

In-Depth [randomized control trial]: This randomized control trial studied eight malaria diagnostic posts in the western Brazilian Amazon, evaluating three primaquine regimens: group 1 received a total primaquine dose of 3.5mg per kilogram over 7 days; group 2 received the same regimen but with observed administration; and group 3 received a total primaquine dose of 7mg per kilogram over 14 days with observed administration. The groups were subsequently monitored for 168 days. Patients who were at least 5 years of age, documented fever, Plasmodium vivax mono-infection, and a parasite density between 100 and 200,000 asexual parasites per cubic millimeter were eligible for the study. Patients with suspected severe malaria or abnormal G6PD activity were excluded since G6PD deficiency can lead to severe hemolysis during primaquine use. The primary outcome measure was the rate of recurrence or treatment failure, defined as clinical deterioration leading to hospitalization with parasitemia. Outcomes in the primary analysis were assessed via Kaplan-Meier survival analysis and an unadjusted Cox proportional-hazards regression model. Based on the analysis, by day 28, 3 Plasmodium vivax recurrences were observed, with 2 in group one and 1 in group two. By day 168, there had been 70 total recurrences, with 24 in group one, 34 in group two, and 12 in group three. On day 168, the recurrence-free percentage was 58% (95% Confidence Interval [CI], 44 to 70) in group 1, 59% (95% CI, 47 to 69) in group 2, and 86% (95% CI, 76 to 92) in group 3. Survival analysis also demonstrated a difference in day 168 recurrence-free percentage of 27% (97.5% CI, 10 to 44) between group 1 and group 2 and a difference of 27% between group 2 and group 3 (96.5% CI, 12 to 42). Overall, this study demonstrated that a higher total dose of primaquine is significantly associated with higher rates of recurrence-free survival in patients with Plasmodium vivax malaria.

RELATED REPORTS

Chlorfenapyr insecticidal nets provide strong protection against malaria in sub-Saharan Africa

Mosquito Nets Provide Survival Benefit in Early Childhood and into Adulthood

#VisualAbstract: Novel malaria vaccine candidate (R21/MM) is safe and highly protective against malaria transmission in African children

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: dose trialmalariaplasmodium vivaxprimaquine
Previous Post

Baricitinib is superior to placebo for treatment of alopecia areata

Next Post

Oral tebipenem pivoxil hydrobromide is effective in treatment of complicated urinary tract infection

RelatedReports

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time
Infectious Disease

Chlorfenapyr insecticidal nets provide strong protection against malaria in sub-Saharan Africa

April 6, 2022
Intrauterine Zika virus infection associated with significant fetal brain abnormalities
Infectious Disease

Mosquito Nets Provide Survival Benefit in Early Childhood and into Adulthood

February 8, 2022
#VisualAbstract: Tezepelumab reduced annual exacerbation rates in patients with severe asthma
StudyGraphics

#VisualAbstract: Novel malaria vaccine candidate (R21/MM) is safe and highly protective against malaria transmission in African children

June 3, 2021
Malarial transmission substantially reduced in endemic Africa
Hematology

Novel malaria vaccine candidate (R21/MM) is safe and highly protective against malaria transmission in African children

June 25, 2021
Next Post
Normal renal ultrasound only rules out high grade vesicoureteral reflux in infants

Oral tebipenem pivoxil hydrobromide is effective in treatment of complicated urinary tract infection

Patient Basics: Stroke Overview

Endovascular therapy for large ischemic strokes provides better functional outcomes

Long-term dual antiplatelet therapy does not increase mortality risk

Rilzabrutinib demonstrates rapid and durable clinical activity for immune thrombocytopenia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.